Affordable Access

deepdyve-link
Publisher Website

The PI3K/AKT Pathway as a Target for Cancer Treatment.

Authors
  • Mayer, Ingrid A1
  • Arteaga, Carlos L1
  • 1 Departments of Medicine and Cancer Biology; Breast Cancer Program, Vanderbilt-Ingram Cancer Center; Vanderbilt University School of Medicine, Nashville, Tennessee 37232; email: [email protected] , [email protected]
Type
Published Article
Journal
Annual Review of Medicine
Publisher
Annual Reviews
Publication Date
Jan 01, 2016
Volume
67
Pages
11–28
Identifiers
DOI: 10.1146/annurev-med-062913-051343
PMID: 26473415
Source
Medline
Keywords
License
Unknown

Abstract

Anticancer targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of this pathway, as a result of these somatic alterations, is associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK are currently in clinical trials, alone or in combination, in both solid tumors and hematologic malignancies. These drugs are the focus of this review.

Report this publication

Statistics

Seen <100 times